In June 2025, the FDA updated its guidance on uterine fibroids, reaffirming them as the most common benign tumors affecting women of childbearing age and emphasizing newer treatment options for managing symptoms like heavy menstrual bleeding. This FDA uterine fibroids 2025 update, detailed in consumer resources and awareness campaigns, highlights fibroids’ impact on reproductive health and calls for better education and access to care. As part of trending women’s health 2025 priorities, including Fibroid Awareness Month in July, the guidance underscores the need for effective, minimally invasive treatments. At Surgical Associates, we align our Women’s Health services with these fibroid facts, advocating Uterine Fibroid Embolization (UFE) as a safe, uterus-preserving option for women in Maryland, DC, and Virginia.
Led by board-certified interventional radiologist Dr. Albert Chun, our team at Surgical Associates integrates FDA-aligned approaches to provide personalized fibroid care. Whether you’re experiencing heavy bleeding, pain, or fertility concerns, understanding this update can empower your decisions. Schedule a screening or consultation at our Camp Springs, Waldorf, Washington D.C., Silver Spring, or Reston locations today. Call (240) 427-1630 or visit www.sacmd.com. Your journey to be Fibroid Free with UFE starts here!
Summarizing the FDA’s 2025 Guidance on Uterine Fibroids
The FDA’s June 30, 2025, consumer update describes uterine fibroids as benign (non-cancerous) tumors or growths in the uterus, most prevalent in women of childbearing age, typically 30-50 years old. These fibroids can vary in size, from pea-sized to grapefruit-sized, and often cause symptoms like heavy menstrual bleeding, pelvic pain, pressure on the bladder or bowels, and complications during pregnancy. The guidance notes that while many fibroids are asymptomatic, they disproportionately affect Black women, leading to earlier onset and more severe issues.
Key fibroid facts from the FDA include:
- Prevalence: Up to 80% of women develop them by age 50, with higher risks for those with family history, obesity, or certain ethnic backgrounds.
- Symptoms and Risks: Heavy bleeding can cause anemia; large fibroids may lead to infertility, miscarriage, or preterm birth.
- Diagnosis: Often via ultrasound, MRI, or hysteroscopy.
The update also highlights newer FDA-approved medicines for managing heavy menstrual bleeding in premenopausal women, such as hormonal therapies like OriaHnn, which reduce bleeding by 50% within the first month in clinical trials. 0 9 Surgical options, including myomectomy and hysterectomy, are mentioned, but the emphasis on minimally invasive alternatives aligns with the trending women’s health 2025 toward preserving fertility and reducing recovery time.
At Surgical Associates, we incorporate these fibroid facts into our care plans, recommending UFE as an FDA-aligned, non-surgical solution that targets fibroids effectively while keeping the uterus intact.
Explore our Vascular Surgery services to learn how UFE fits into modern fibroid management in Maryland, DC, and Virginia.
What the FDA Update Means for Women of Childbearing Age
The FDA’s focus on fibroids as a major issue for childbearing-age women underscores the need for treatments that support reproductive health. In 2025, with awareness campaigns like the July Instagram post from the FDA highlighting symptoms and detection, women are encouraged to seek early intervention to avoid complications like infertility or chronic pain.
For you, this means prioritizing options that align with your life stage—whether planning a family or managing symptoms without disrupting daily routines. The update’s mention of newer medicines for heavy bleeding is promising, but for lasting relief, procedures like UFE stand out. UFE, which the FDA has long recognized as safe and effective, shrinks fibroids by blocking their blood supply, offering 85-90% symptom improvement without removing the uterus. This is particularly relevant for premenopausal women, as it preserves fertility amid fibroids’ potential to cause pregnancy issues.
Dr. Albert Chun at Surgical Associates tailors UFE to meet these needs, ensuring care that matches FDA guidance for better outcomes.
Visit our About Us page to see how we support childbearing-age women with trending women’s health 2025 strategies.
Advocating UFE: A Key Solution in Light of FDA Guidance
While the FDA update discusses medicines and surgery, it opens the door for advocating UFE as a preferred minimally invasive option. UFE directly addresses fibroid facts like heavy bleeding by reducing fibroid size by 50-60% within months, often eliminating the need for ongoing medication. Unlike hysterectomy, which ends fertility—a critical concern for childbearing-age women—UFE preserves the uterus and has a quick recovery (1-2 weeks).
In 2025, with FDA approvals for related treatments like focused ultrasound (updated June 5, 2025), UFE complements these by offering broad efficacy for multiple fibroids. For women in Maryland, DC, and Virginia, Surgical Associates provides FDA-aligned UFE, ensuring safe, effective care that aligns with the update’s emphasis on managing symptoms without unnecessary risks.
Schedule a screening or consultation at our Camp Springs, Waldorf, Washington D.C., Silver Spring, or Reston locations today. Call (240) 427-1630 or visit www.sacmd.com. Your journey to be Fibroid Free with UFE starts here!
Addressing Disparities and Awareness in 2025
The FDA’s July 2025 Fibroid Awareness Month efforts highlight disparities, noting fibroids’ greater impact on Black women of childbearing age. This ties into the trending women’s health 2025, with calls for equitable access to treatments like UFE, which offers lower costs and faster recovery than surgery.
At Surgical Associates, we prioritize inclusive care, helping diverse populations navigate fibroid facts and options.
Patient Perspectives: Aligning with FDA Guidance
Women at Surgical Associates often share how UFE resolved heavy bleeding post-FDA-recommended evaluations: “Knowing fibroids are benign but treatable gave me confidence—UFE was the perfect fit.”
Apply FDA Insights to Your Fibroid Care
The FDA uterine fibroids 2025 update empowers women with fibroid facts, advocating for effective treatments like UFE that support childbearing-age health. If you’re ready for relief in Maryland, DC, or Virginia, Surgical Associates and Dr. Albert Chun offer FDA-aligned care. Schedule a screening or consultation at our Camp Springs, Waldorf, Washington D.C., Silver Spring, or Reston locations today. Call (240) 427-1630 or visit www.sacmd.com. Your journey to be Fibroid Free with UFE starts here!
Get FDA-aligned care at sacmd.com—consult now.

Dr. Rahbar is an esteemed vascular surgeon at Surgical Associates, known for their exceptional contributions to the field of vascular surgery. As a board-certified vascular surgeon with over 20 years of invaluable experience, Dr. Rahbar is a respected authority in the medical community serving Reston, VA, Maryland & DC. His unwavering dedication to providing advanced care for patients with diseases of the arteries and veins has earned them a reputation for excellence. Dr. Rahbar’s work embodies a passion for precision and compassion, improving the lives of those they serve, one procedure at a time.